Loading patent…
AssigneesBioAxone BioSciences, Inc., Neurelis, Inc.
InventorsKenneth M. ROSEN, Matthew D. ABBINANTI, Lisa MCKERRACHER, Stuart MADDEN
Estimating the term…
The present disclosure relates to crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-amine, salts thereof, pharmaceutical compositions thereof, pharmaceutical compositions comprising crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-amine, salts thereof and methods of treatment of neurological conditions including cavernous angioma, cerebral aneurysm, stroke, subarachnoid hemorrhage, vasospasm after subarachnoid hemorrhage, traumatic brain injury, spinal cord injury, spinal cord injury stroke, seizures, hereditary hemorrhagic telangiectasis, cerebral arteriovascular malformations, sporadic cavernous angioma lesion, cerebral cavernous malformation, or combinations thereof, using the same.
A pharmaceutical formulation comprising a therapeutically effective amount of a crystalline form of a compound of Formula I:
A crystalline form of a compound of Formula I:
A crystalline form of a compound of Formula I:
A pharmaceutical formulation comprising a therapeutically effective amount of a crystalline form of a compound of Formula I:
A method for treating a patient having a neurological condition, comprising administering a pharmaceutical formulation which comprises a therapeutically effective amount of a crystalline form of a compound of Formula I:
Dependencies are inferred from the claim text.